全文获取类型
收费全文 | 696篇 |
免费 | 42篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 44篇 |
妇产科学 | 12篇 |
基础医学 | 92篇 |
口腔科学 | 28篇 |
临床医学 | 44篇 |
内科学 | 121篇 |
皮肤病学 | 16篇 |
神经病学 | 52篇 |
特种医学 | 144篇 |
外国民族医学 | 1篇 |
外科学 | 38篇 |
综合类 | 51篇 |
预防医学 | 36篇 |
眼科学 | 5篇 |
药学 | 21篇 |
中国医学 | 4篇 |
肿瘤学 | 32篇 |
出版年
2023年 | 3篇 |
2021年 | 9篇 |
2020年 | 9篇 |
2019年 | 7篇 |
2018年 | 14篇 |
2017年 | 12篇 |
2016年 | 18篇 |
2015年 | 13篇 |
2014年 | 19篇 |
2013年 | 34篇 |
2012年 | 31篇 |
2011年 | 21篇 |
2010年 | 44篇 |
2009年 | 44篇 |
2008年 | 31篇 |
2007年 | 23篇 |
2006年 | 12篇 |
2005年 | 12篇 |
2004年 | 6篇 |
2003年 | 4篇 |
2002年 | 4篇 |
2001年 | 5篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 34篇 |
1997年 | 33篇 |
1996年 | 34篇 |
1995年 | 35篇 |
1994年 | 23篇 |
1993年 | 20篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 15篇 |
1988年 | 14篇 |
1987年 | 10篇 |
1986年 | 13篇 |
1985年 | 9篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 15篇 |
1979年 | 4篇 |
1978年 | 8篇 |
1977年 | 2篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1950年 | 1篇 |
1949年 | 1篇 |
排序方式: 共有742条查询结果,搜索用时 0 毫秒
741.
Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB 《Blood》1996,88(2):542-551
Binding of urokinase-type plasminogen activator (uPA) to its glycosylphosphatidylinositol-anchored receptor (uPAR) initiates signal transduction, adhesion, and migration in certain cell types. To determine whether some of these activities may be mediated by associations between the uPA/uPAR complex and other cell surface proteins, we studied the binding of complexes composed of recombinant, soluble uPA receptor (suPAR) and single chain uPA (scuPA) to a cell line (LM-TK- fibroblasts) that does not express glycosylphosphatidylinositol (GPI)-anchored proteins to eliminate potential competition by endogenous uPA receptors. scuPA induced the binding of suPAR to LM-TK- cells. Binding of labeled suPAR/scuPA was inhibited by unlabeled complex, but not by scuPA or suPAR added separately, indicating cellular binding sites had been formed that are not present in either component. Binding of the complex was inhibited by low molecular weight uPA (LMW-uPA) indicating exposure of an epitope found normally in the isolated B chain of two chain uPA (tcuPA), but hidden in soluble scuPA. Binding of LMW-uPA was independent of its catalytic site and was associated with retention of its enzymatic activity. Additional cell binding epitopes were generated within suPAR itself by the aminoterminal fragment of scuPA, which itself does not bind to LM-TK- cells. When scuPA bound to suPAR, a binding site for alpha 2-macroglobulin receptor/LDL receptor-related protein (alpha 2 MR/LRP) was lost, while binding sites for cell-associated vitronectin and thrombospondin were induced. In accord with this, the internalization and degradation of cell-associated tcuPA and tcuPA-PAI- 1 complexes proceeded less efficiently in the presence of suPAR. Further, little degradation of suPAR was detected, suggesting that cell- bound complex dissociated during the initial stages of endocytosis. Thus, the interaction of scuPA with its receptor causes multiple functional changes within the complex including the dis-appearance of an epitope in scuPA involved in its clearance from the cell surface and the generation of novel epitopes that promote its binding to proteins involved in cell adhesion and signal transduction. 相似文献
742.
AA Abou-Elella ; TA Camarillo ; MB Allen ; S Barclay ; JA Pierce ; HK Holland ; JR Wingard ; RA Bray ; GE Rodey ; CD Hillyer 《Transfusion》1995,35(11):931-935
BACKGROUND : Bone marrow transplant (BMT) patients, although immunosuppressed, are at risk for the development of red cell (RBC) and HLA antibodies, and they often are given filtered blood in an effort to prevent the latter complication. This study attempts to determine the rate of formation and the specificity of both RBC and HLA alloantibodies in this patient population. STUDY DESIGN AND METHODS : BMT patients (148 received autologous marrow; 45 received allogeneic marrow) from an 18-month period, including patients with leukemia (57 patients), lymphoma (54), breast cancer (68), myeloma (8), myelodysplastic syndrome (5), and aplastic anemia (1), were studied to determine the rate of alloantibody formation to RBC and HLA antigens. A total of 2,410 RBC antibody screens were performed. The patients received 3,921 packed RBCs and 5,915 single-donor platelet units; all were irradiated and administered via white cell-reduction filters. RESULTS : Seven (3.6%) of 193 patients had RBC antibodies upon hospital admission. Four (2.1%) of 193 developed RBC antibodies during the course of BMT: 3 patients had one RBC antibody and 1 patient had two RBC antibodies. RBC antibodies included anti-E (n = 2), anti-M (n = 1), anti-Jkb (n = 1), and anti-Lu14 (n = 1). Thus, 98 percent of patients (189/193) did not develop new (182/186) or additional (7/7) RBC antibodies during BMT. BMT patients were also screened weekly for HLA antibody formation (60-cell panel). Upon admission, 170 (85%) patients were negative. Of these, 8 (4.7%) developed persistent HLA antibodies (mean panel-reactive antibody score, 33 +/? 29%) and 9 (5.3%) were variably positive. Thus, in our setting and population, RBC antibody formation was 0.1 percent per unit transfused, and the HLA alloimmunization rate was 5 to 10 percent. CONCLUSION : As RBC antibody screens are done every Monday, Wednesday, and Friday on this BMT service and as RBC antibody formation is low in these patients, screening for unexpected antibodies might be possible on a more infrequent basis. Also, the rate of HLA alloimmunization in this population receiving filtered blood components is low. 相似文献